Protein Kinase Inhibitors: all 15,278 studies that test it

Page 116 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line ChemotherapyCompletedNCT02448329Phase 2
• Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line ChemotherapyCompletedNCT02448290Phase 2
• Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung CancerTerminatedNCT02448251Phase 1
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaWithdrawnNCT02447939Phase 1
• Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid TumorsCompletedNCT02447419Phase 2
• Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line TreatmentCompletedNCT02447406Phase 1/2
• Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line TreatmentCompletedNCT02447380Phase 2
• CML Treated With Bosutinib After RelapseCompletedNCT02445742Phase 2
• Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)CompletedNCT02445131Phase 2
• MLN8237 to Treat Children With Relapsed/Refractory Solid TumorsCompletedNCT02444884Phase 1
• Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer TherapyCompletedNCT02444819Phase 2
• Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CACompletedNCT02443818Phase 2
• A Phase 1 Study of KBP-5209 in Patients With Advanced Solid TumorsCompletedNCT02442414Phase 1
• Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive MalignanciesCompletedNCT02441465Phase 1
• Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer PatientsWithdrawnNCT02439723Phase 1
• Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid TumorsCompletedNCT02439489Phase 1
• Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous DocetaxelTerminatedNCT02439346Phase 1
• PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)TerminatedNCT02438761Phase 2
• Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT02436707Phase 2
• ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With LeucovorinStatus unknownNCT02435927Phase 1
• A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET AmplificationCompletedNCT02435121Phase 2
• A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line ChemotherapyCompletedNCT02435108Phase 2
• Relative Bioavailability Study of CC-292CompletedNCT02433457Phase 1
• Open Label Study of Fostamatinib in the Treatment of IgA NephropathyWithdrawnNCT02433236Phase 2
• A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid TumorsCompletedNCT02432326Phase 1
• Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011CompletedNCT02431481Phase 1
• Chemotherapy of NSCLC With or Without IcotinibStatus unknownNCT02430974Phase 2
• Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475Status unknownNCT02430363Phase 1/2
• Trial With Gemcitabine and Rapamycin in Second Line of Metastatic OsteosarcomaCompletedNCT02429973Phase 2
• Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and NeckTerminatedNCT02429089Phase 1
• A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid TumorsCompletedNCT02428712Phase 1/2
• Ponatinib for FLT3-ITD Acute Myelogenous LeukemiaCompletedNCT02428543Phase 1/2
• A Study of GSK2256098 and Trametinib in Advanced Pancreatic CancerCompletedNCT02428270Phase 2
• Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant MelanomaWithdrawnNCT02427893Phase 3
• Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT02427620Phase 2
• Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOXTerminatedNCT02425683Phase 2
• Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular CarcinomaCompletedNCT02425605Phase 2
• PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerCompletedNCT02423603Phase 2
• First-in-Human Single Ascending Dose of SHR0302Status unknownNCT02423538Phase 1
• Safety Study of Afatinib for Brain CancerCompletedNCT02423525Phase 1
• Radotinib as 3rd or Later Line Therapy in CP-CMLStatus unknownNCT02422719Phase 2
• A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced TumorsCompletedNCT02422589Phase 1
• A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or TrastuzumabStatus unknownNCT02422199Phase 1/2
• Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02421185Phase 1/2
• A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)CompletedNCT02421042Phase 1
• Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine GliomaCompletedNCT02420613Phase 1
• AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)WithdrawnNCT02420587Phase 2
• Pilot Study of Crizotinib in Relapsed ALK+ LymphomasCompletedNCT02419287Phase 2
• Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed RegimensCompletedNCT02418689Phase 2
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 'Ursa Complex Soft Cap. (UDCA-004)' in Patients With Physical Fatigue.CompletedNCT02418130Phase 4
• Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver DysfunctionCompletedNCT02415777Phase 4
• A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric CancerCompletedNCT02415023Phase 1/2
• Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or LymphomaTerminatedNCT02414724Phase 1
• Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GISTActive, not recruitingNCT02413736Phase 3
• Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced MelanomaTerminatedNCT02410863Phase 2
• A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric CancerStatus unknownNCT02409199Phase 2/3
• Phase I Trial of VS-6766 Alone and in Combination With EverolimusCompletedNCT02407509Phase 1
• MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasActive, not recruitingNCT02407405Phase 2
• Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung CancerStatus unknownNCT02407366Phase 2
• A Multiple-Ascending Dose Study of MS-553 in Healthy VolunteersCompletedNCT02406989Phase 1
• Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCCWithdrawnNCT02406508Phase 2
• Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric CarcinomaCompletedNCT02406170Phase 1/2
• Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573CompletedNCT02405065Phase 1
• Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast CancerCompletedNCT02404844Phase 2
• High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon MutationStatus unknownNCT02404675Phase 4
• Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerStatus unknownNCT02404051Phase 3
• Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal WomenCompletedNCT02400567Phase 2
• A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaWithdrawnNCT02400385Phase 2
• A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal CancerCompletedNCT02399943Phase 2
• Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung AdenocarcinomaStatus unknownNCT02399566Phase 4
• Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibTerminatedNCT02398825Phase 2
• Japanese Phase I Study of AZD2014 in Advanced Solid MalignanciesCompletedNCT02398747Phase 1
• A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.Status unknownNCT02398552Phase 2
• Regorafenib Phase I Study in Mainland Chinese PatientsCompletedNCT02398513Phase 1
• Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial CancerActive, not recruitingNCT02397083Phase 2
• Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast CancerStatus unknownNCT02396108Phase 1/2
• Overcoming Endocrine Resistance in Metastatic Breast CancerStatus unknownNCT02394496Phase 3
• Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland CarcinomaCompletedNCT02393820Phase 2
• Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingNCT02393625Phase 1
• Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）CompletedNCT02390947Phase 3
• A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy AdultsCompletedNCT02390609Phase 1
• Roniciclib Mass Balance StudyCompletedNCT02390154Phase 1
• Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to DasatinibStatus unknownNCT02389920Phase 4
• PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibCompletedNCT02389842Phase 1
• Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid TumorsActive, not recruitingNCT02389309Phase 1
• A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone SarcomasCompletedNCT02389244Phase 2
• Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）CompletedNCT02388919Phase 2/3
• Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011CompletedNCT02388620Phase 1
• Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
• INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02386826Phase 1
• CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
• Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract CancerCompletedNCT02386397Phase 1/2
• Comparative Bioavailability Study of UDCACompletedNCT02385032Phase 1
• Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian CancerCompletedNCT02383251Phase 2
• A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibTerminatedNCT02382549Early Phase 1
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
• Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell MalignancyCompletedNCT02381080Phase 1
• Multiple Treatments for Ebola Virus Disease (EVD)Status unknownNCT02380625Phase 1/2
• Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsCompletedNCT02379416Phase 1
• Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerStatus unknownNCT02378389Phase 1

← Protein Kinase Inhibitors overview